Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 67

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 67
---
 below are not considered to be prepared in accordance with U.S. GAAP and have not been prepared as pro forma
results under applicable regulations, may not reflect the actual results we would have achieved had the Business Combination occurred
at the beginning of fiscal 2024, and should not be viewed as a substitute for the results of operations of the Predecessor and Successor
periods presented in accordance with U.S. GAAP.

<div align='center'>38</div>

Comparison of the period commencing July 24, 2024 through December 31, 2024 (Successor and Predecessor) to the period commencing July 24, 2024 through December 31, 2024 (Predecessor)

The following table is data derived from the
Consolidated Statement of Operations (in thousands) and the discussions that follow are in approximate amounts.

|                                     |     | Successor and Predecessor |       |   |     |         Predecessor |     |
|                                     |     |                   For the 
                    period 
        commencing July 24 |       |   |     |             For the 
              period 
  commencing July 24 |     |
|                                     |     |       through December 31 |       |   |     | through December 31 |     |
|                                     |     |                      2024 |       |   |     |                2024 |     |
|                                     |     |                 Unaudited |       |   |     |           Unaudited |     |
| Operating expenses                  |     |                           |       |   |     |                     |     |
| Research and development expenses   |     |                           |   996 |   |     |                     | 670 |
| General and administrative expenses |     |                           | 1,153 |   |     |                     | 103 |
| Operating loss                      |     |                           | 2,149 |   |     |                     | 773 |
| Financial expense (income), net     |     |                           |   (65 | ) |     |                     |  10 |
| Net loss and comprehensive loss     |     |                           | 2,084 |   |     |                     | 783 |

Research and Development Expenses

Successor’s and Predecessor’s
research and development expenses totaled $996 thousand for the period commencing July 24, 2024 through December 31, 2024, representing
an increase of $326 thousand, or